Ascendis Pharma (ASND) Misses Q4 EPS by 40c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR0.55), EUR0.40 worse than the analyst estimate of (EUR0.15). Revenue for the quarter came in at EUR240 million versus the consensus estimate of EUR245.68 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)